Focus-X Therapeutics Inc.

https://www.focus-xtx.com

Founded in 2020, Focus-X has developed a proprietary engineering platform to develop peptide radioligands that precisely deliver alpha or beta emitters to breakdown cancer cell DNA. The platform enables high-quality optimization of peptide radioligand vectors for key pharmaceutical attributes such as biodistribution, binding affinity and in vivo stability. Such optimization can present significant challenges to other ligand targeting compounds such as antibodies. The company has focused on both validated targets and new mechanisms. Focus-X has established a substantial pipeline. The company’s two lead compounds in development are a prostate specific membrane antigen (PMSA)-targeted peptide for the treatment of metastatic castration resistant prostate cancer and a neurotensin receptor type 1 (NTSR1)-targeted peptide for the treatment of pancreatic cancer. The PMSA-targeted compound is currently undergoing an investigator-initiated imaging study. Focus-X has six other programs in earlier stages of development. *

	Start	2020-01-01 established
	Group	Full-Life Technologies (Group)
	Industry	RADIOPHARMACEUTICAL (RPT)
	Industry 2	UniRDC™ discovery technology
	Person	Liu, Fa (Focus-X Therapeutics 202211 CEO + Co-Founder)

	Street	64 Lakeview Avenue
	City	07069 Watchung, NJ
		Address record changed: 2022-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Full-Life Technologies Ltd.. (11/29/22). "Press Release: Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-focused Radiopharmaceutical Pipeline". Brussels, Watchung, NJ & Shanghai.

		Record changed: 2024-01-21